Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma.

Cancer research - 15 Aug 2025

Balakrishnan Ilango, Madhavan Krishna, Pierce Angela, Michlin Joshua, Brunt Breauna, Lakshmanachetty Senthilnath, Wang Dong, DeSisto John, Nuss Zachary James, Davidson Nathan, Walker Faye, Suresh Ammu, Donson Andrew, Sanford Bridget, Jones Kenneth L, Danis Etienne P, Mitra Siddhartha S, Green Adam L, Dahl Nathan, Vibhakar Rajeev, Venkataraman Sujatha

Abstract excerpt

Diffuse midline gliomas (DMG) are devastating brain tumors that occur primarily in children. The salient feature of these tumors is the presence of a H3K27M mutation (K27M), associated with the worst prognosis. Development of effective strategies for treating K27M+ DMG is desperately needed to help improve patient outcomes. In this study, we identified the cell surface antigen CD99 as notably expressed in DMGs,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal
Share to Apoptosis

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Brain Neoplasms

Share to Cell Line, Tumor

Share to Glioma

Share to Mutation

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 40424183
DOI: 10.1158/0008-5472.CAN-24-5027
PMCID: PMC12588558

Genes

CD99

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 10 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development of an Anti-CD99 Antibody Enables Targeting of Diffuse Midline Glioma.PMID 40424183Read ↗

Targeting Diffuse Midline Glioma with a novel anti-CD99 AntibodySemantic proximity Read ↗

Bench-to-bedside investigations of H3 K27-altered diffuse midline glioma: drug targets and potential pharmacotherapies.Semantic proximity Read ↗

CD155 regulates tumor growth and immune evasion in diffuse midline gliomaSemantic proximity Read ↗

Oncohistone inhibition reshapes tumor–microenvironment communication in Diffuse Midline Glioma (DMG)Semantic proximity Read ↗

H3K27M Mutation Reshapes the Antigenic Landscape in Diffuse Midline GliomaSemantic proximity Read ↗

H3 K27M-mutant diffuse midline glioma with osseous metastases: A case report and a literature review.Semantic proximity Read ↗

Radiotherapy and radio-sensitization in H3K27M -mutated diffuse midline gliomas.Semantic proximity Read ↗

Clinicohistoradiological and surgical outcome in diffuse midline glioma.Semantic proximity Read ↗

Differences in survival prognosticators between children and adults with H3K27M-mutant diffuse midline glioma.Semantic proximity Read ↗

Selective DRD2 antagonist and ClpP agonist ONC201 in a recurrent non-midline H3 K27M-mutant glioma cohort.Semantic proximity Read ↗

H3K27M diffuse midline glioma is homologous recombination defective and sensitized to radiotherapy and NK cell-mediated antitumor immunity by PARP inhibitionSemantic proximity Read ↗

Dual Targeting of Histone Deacetylases and MYC as Potential Treatment Strategy for H3-K27M Pediatric GliomasSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.